Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$3.40 +1.5%	$2.82	$2.12 ▼ $5.80	$332.75M	1.94	1.55 million shs	1.67 million shs
MBX MBX Biosciences	$10.28 +1.8%	$10.62	$4.81 ▼ $27.50	$343.60M	N/A	249,270 shs	184,797 shs
TERN Terns Pharmaceuticals	$4.00 +2.6%	$3.12	$1.87 ▼ $11.40	$340.61M	-0.18	1.50 million shs	749,211 shs
UNCY Unicycive Therapeutics	$0.67 -2.8%	$0.63	$0.20 ▼ $1.10	$86.81M	2.01	2.05 million shs	7.57 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	-5.37%	-6.42%	+40.76%	+12.42%	+22.71%
MBX MBX Biosciences	-3.81%	-11.79%	-9.50%	+20.24%	+1,009,999,900.00%
TERN Terns Pharmaceuticals	-2.74%	-3.94%	+35.42%	+23.42%	-51.01%
UNCY Unicycive Therapeutics	-8.96%	+29.05%	+15.24%	+3.43%	+5.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.6791 of 5 stars	3.5	1.0	0.0	3.7	0.0	0.0
MBX MBX Biosciences	2.114 of 5 stars	3.5	0.0	0.0	0.0	3.3	0.6
TERN Terns Pharmaceuticals	4.3541 of 5 stars	3.3	2.0	4.1	3.5	3.3	0.6
UNCY Unicycive Therapeutics	3.7201 of 5 stars	3.8	5.0	0.0	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.14	198.32% Upside
MBX MBX Biosciences	3.00	Buy	$37.50	264.79% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	290.63% Upside
UNCY Unicycive Therapeutics	3.50	Strong Buy	$6.00	798.88% Upside

Current Analyst Ratings Breakdown

Latest UNCY, AQST, MBX, and TERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$9.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/13/2025	TERN Terns Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $15.00
4/21/2025	TERN Terns Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
4/21/2025	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
4/11/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/10/2025	MBX MBX Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
4/10/2025	MBX MBX Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00 ➝ $44.00
4/10/2025	MBX MBX Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$38.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$57.56M	5.87	N/A	N/A	($0.66) per share	-5.15
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.07 per share	N/A
UNCY Unicycive Therapeutics	$680K	124.09	N/A	N/A	$0.07 per share	9.54

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.59	N/A	N/A	-100.02%	N/A	-50.31%	8/5/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	-$88.85M	-$1.09	N/A	N/A	N/A	-28.81%	-27.55%	8/4/2025 (Estimated)
UNCY Unicycive Therapeutics	-$36.73M	-$0.51	N/A	N/A	N/A	-277.30%	-61.53%	N/A

Latest UNCY, AQST, MBX, and TERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	UNCY Unicycive Therapeutics	-$0.14	-$0.05	+$0.09	-$0.05	N/A	N/A
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/8/2025	Q1 2025	TERN Terns Pharmaceuticals	-$0.29	-$0.26	+$0.03	-$0.26	N/A	N/A
3/27/2025	Q4 2024	UNCY Unicycive Therapeutics	-$0.13	-$0.26	-$0.13	-$0.26	N/A	N/A
3/20/2025	Q4 2024	TERN Terns Pharmaceuticals	-$0.30	-$0.24	+$0.06	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	4.87	4.48
MBX MBX Biosciences	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	30.89	30.89
UNCY Unicycive Therapeutics	N/A	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
MBX MBX Biosciences	N/A
TERN Terns Pharmaceuticals	98.26%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
MBX MBX Biosciences	52.19%
TERN Terns Pharmaceuticals	1.50%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.33 million	91.03 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A
TERN Terns Pharmaceuticals	40	87.34 million	86.03 million	Not Optionable
UNCY Unicycive Therapeutics	9	126.41 million	107.71 million	Not Optionable

UNCY, AQST, MBX, and TERN Headlines

Recent News About These Companies

Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing

June 18 at 7:40 PM | investing.com

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

June 17 at 7:00 AM | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 46.4% in May

June 15 at 10:09 AM | marketbeat.com

Brookline Capital Management Weighs in on UNCY Q3 Earnings

June 14, 2025 | americanbankingnews.com

UNCY Q3 EPS Forecast Raised by Brookline Capital Management

June 12, 2025 | marketbeat.com

Kaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations

June 11, 2025 | theglobeandmail.com

Retail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28m

June 11, 2025 | finance.yahoo.com

Unicycive Shares Slide as FDA Flags Issues Related to Kidney Drug Application

June 10, 2025 | marketwatch.com

Unicycive Therapeutics stock tumbles after FDA flags manufacturing issues

June 10, 2025 | investing.com

Unicycive Therapeutics Addresses FDA Deficiencies in OLC NDA Process, Awaiting Final Decision by June 2025

June 10, 2025 | quiverquant.com

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

June 10, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Drop in Short Interest

June 3, 2025 | marketbeat.com

What is HC Wainwright's Estimate for UNCY Q2 Earnings?

May 30, 2025 | marketbeat.com

Q4 Earnings Estimate for UNCY Issued By HC Wainwright

May 29, 2025 | marketbeat.com

Unicycive Therapeutics' (UNCY) "Buy" Rating Reiterated at HC Wainwright

May 28, 2025 | marketbeat.com

Unicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor Conferences

May 22, 2025 | quiverquant.com

Unicycive Therapeutics to Present at Upcoming Investor Conferences

May 22, 2025 | globenewswire.com

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

May 21, 2025 | globenewswire.com

Q2 Earnings Forecast for UNCY Issued By Noble Financial

May 20, 2025 | marketbeat.com

Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | finanznachrichten.de

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY, AQST, MBX, and TERN Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$3.40 +0.05 (+1.49%)

Closing price 04:00 PM Eastern

Extended Trading

$3.44 +0.04 (+1.18%)

As of 07:22 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

MBX Biosciences NYSE:MBX

$10.28 +0.18 (+1.78%)

Closing price 04:00 PM Eastern

Extended Trading

$10.28 0.00 (-0.05%)

As of 04:04 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Terns Pharmaceuticals NASDAQ:TERN

$4.00 +0.10 (+2.56%)

Closing price 04:00 PM Eastern

Extended Trading

$4.00 +0.00 (+0.12%)

As of 07:51 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Unicycive Therapeutics NASDAQ:UNCY

$0.67 -0.02 (-2.80%)

Closing price 04:00 PM Eastern

Extended Trading

$0.64 -0.03 (-4.87%)

As of 07:49 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time